Neuland Laboratories shares surge 7.65% after blockbuster Q4 results. The pharmaceutical company reported consolidated net profit jumping 660% to Rs 213 crore, while revenue more than doubled to Rs 776.3 crore year-on-year. EBITDA skyrocketed to Rs 319 crore from Rs 58 crore, demonstrating significant margin expansion and operational efficiency. For full year FY26, total income reached Rs 2,053.1 crore with EBITDA at Rs 603.4 crore. The stock has gained nearly 20% in the past month and remains trading above all key moving averages with RSI at 67.9, indicating strong momentum. Management highlighted healthy business visibility driven by commercial and near-commercial molecules, with strategic investments in peptide manufacturing and new R&D centre progressing as planned.
Post from MarketNews_en
Log in to interact with content.